药企龙头突发公告，60岁董事长逝世，当日上午还在主持会议

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Excipients, is a significant event for the company, which has been under his leadership since its inception. The company is expected to maintain its operations and governance structure despite this loss [4][7][10]. Company Overview - Shanhe Pharmaceutical Excipients was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients. It has become a leading player in the domestic pharmaceutical excipients industry and was listed on the Shenzhen Stock Exchange in May 2015 [10]. - As of August 27, the company's market capitalization was approximately 3.28 billion yuan [10]. Leadership Transition - Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the total shares, making him the controlling shareholder and actual controller of the company [7]. - Following his passing, the company announced that the board of directors would not fall below the legal number of members, ensuring normal operations. Song Daocai, a current board member and general manager, will temporarily assume the role of chairman until a new chairman is elected [9][10]. Financial Performance - For the first half of 2025, Shanhe Pharmaceutical reported a revenue of 471 million yuan, a year-on-year increase of 4.65%. However, the net profit attributable to shareholders decreased by 2.61% to approximately 93 million yuan [11][12]. - The company’s cash flow from operating activities saw a significant increase of 108.53%, reaching approximately 80 million yuan [12]. - Basic earnings per share decreased by 2.44% to 0.40 yuan, while diluted earnings per share fell by 5.00% to 0.38 yuan [12]. Market Reaction - Following the news of Yin Zhenglong's passing, Shanhe Pharmaceutical's stock price dropped by 2.65%, closing at 13.96 yuan per share on August 27 [13].